BEAT Biotelemetry Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BEAT

Price (delayed)

$71.85

Market cap

$2.46B

P/E Ratio

135.57

Dividend/share

N/A

EPS

$0.53

Enterprise value

$2.53B

Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.gobio.com/

Highlights

The company's quick ratio rose by 20% YoY and by 11% QoQ
The debt has contracted by 19% YoY
The stock's price to earnings (P/E) is 197% more than its 5-year quarterly average of 45.7 and 101% more than its last 4 quarters average of 67.3
The net income has dropped by 54% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of BEAT
Market
Shares outstanding
34.26M
Market cap
$2.46B
Enterprise value
$2.53B
Valuations
Price to earnings (P/E)
135.57
Price to book (P/B)
6.2
Price to sales (P/S)
5.62
EV/EBIT
66.51
EV/EBITDA
30.34
EV/Sales
5.76
Earnings
Revenue
$438.83M
EBIT
$38.04M
EBITDA
$83.39M
Free cash flow
$71.48M
Per share
EPS
$0.53
Free cash flow per share
$2.08
Book value per share
$11.6
Revenue per share
$12.79
TBVPS
$8.81
Balance sheet
Total assets
$737.1M
Total liabilities
$340.71M
Debt
$158.33M
Equity
$396.38M
Working capital
$122.37M
Liquidity
Debt to equity
0.4
Current ratio
2.8
Quick ratio
2.63
Net debt/EBITDA
0.82
Margins
EBITDA margin
19%
Gross margin
61.7%
Net margin
4%
Operating margin
9.2%
Efficiency
Return on assets
2.5%
Return on equity
4.6%
Return on invested capital
11.7%
Return on capital employed
5.7%
Return on sales
8.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BEAT stock price

How has the Biotelemetry stock price performed over time
Intraday
-0.07%
1 week
-0.11%
1 month
-0.51%
1 year
32.76%
YTD
-0.32%
QTD
-0.32%

Financial performance

How have Biotelemetry's revenue and profit performed over time
Revenue
$438.83M
Gross profit
$270.94M
Operating income
$40.3M
Net income
$17.68M
Gross margin
61.7%
Net margin
4%
The net margin has plunged by 56% YoY and by 9% from the previous quarter
The net income has dropped by 54% year-on-year and by 8% since the previous quarter
The operating margin has contracted by 32% YoY and by 8% from the previous quarter
The operating income has declined by 31% year-on-year and by 7% since the previous quarter

Growth

What is Biotelemetry's growth rate over time

Valuation

What is Biotelemetry stock price valuation
P/E
135.57
P/B
6.2
P/S
5.62
EV/EBIT
66.51
EV/EBITDA
30.34
EV/Sales
5.76
The stock's price to earnings (P/E) is 197% more than its 5-year quarterly average of 45.7 and 101% more than its last 4 quarters average of 67.3
BEAT's EPS has shrunk by 54% YoY and by 7% QoQ
BEAT's P/B is 59% above its last 4 quarters average of 3.9 and 27% above its 5-year quarterly average of 4.9
The equity is up by 10% year-on-year and by 3.3% since the previous quarter
The price to sales (P/S) is 65% more than the last 4 quarters average of 3.4 and 56% more than the 5-year quarterly average of 3.6

Efficiency

How efficient is Biotelemetry business performance
Biotelemetry's return on equity has shrunk by 60% YoY and by 12% QoQ
Biotelemetry's ROA has plunged by 58% YoY and by 7% from the previous quarter
BEAT's return on invested capital is down by 38% year-on-year and by 6% since the previous quarter
BEAT's ROS is down by 35% YoY and by 6% QoQ

Dividends

What is BEAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAT.

Financial health

How did Biotelemetry financials performed over time
Biotelemetry's total assets is 116% higher than its total liabilities
The company's quick ratio rose by 20% YoY and by 11% QoQ
BEAT's current ratio is up by 14% year-on-year and by 11% since the previous quarter
The debt is 60% less than the equity
The company's debt to equity fell by 26% YoY and by 2.4% QoQ
The equity is up by 10% year-on-year and by 3.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.